These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38555998)
1. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy. Wang S; Cen D; Zhang C J Pharm Sci; 2024 Jul; 113(7):1927-1933. PubMed ID: 38555998 [TBL] [Abstract][Full Text] [Related]
2. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy. Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891 [TBL] [Abstract][Full Text] [Related]
3. The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells. Han H; Jin Q; Wang Y; Chen Y; Ji J Chem Commun (Camb); 2015 Dec; 51(98):17435-8. PubMed ID: 26468509 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360 [TBL] [Abstract][Full Text] [Related]
5. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964 [TBL] [Abstract][Full Text] [Related]
6. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment. Han H; Wang J; Chen T; Yin L; Jin Q; Ji J J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445 [TBL] [Abstract][Full Text] [Related]
7. A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly. Dai Y; Ma X; Zhang Y; Chen K; Tang JZ; Gong Q; Luo K Biomater Sci; 2018 Nov; 6(11):2976-2986. PubMed ID: 30255871 [TBL] [Abstract][Full Text] [Related]
8. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944 [TBL] [Abstract][Full Text] [Related]
9. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758 [TBL] [Abstract][Full Text] [Related]
10. Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy. Han H; Wang H; Chen Y; Li Z; Wang Y; Jin Q; Ji J Nanoscale; 2016 Jan; 8(1):283-91. PubMed ID: 26608864 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies. Tang Z; Feng W; Yang Y; Wang Q Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830 [TBL] [Abstract][Full Text] [Related]
13. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. Matsushita K; Okuda T; Mori S; Konno M; Eguchi H; Asai A; Koseki J; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Kasahara Y; Morihiro K; Satoh T; Doki Y; Mori M; Ishii H; Obika S ChemMedChem; 2019 Aug; 14(15):1384-1391. PubMed ID: 31207139 [TBL] [Abstract][Full Text] [Related]
14. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130 [TBL] [Abstract][Full Text] [Related]
15. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669 [TBL] [Abstract][Full Text] [Related]
16. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy. Lu Z; Su J; Li Z; Zhan Y; Ye D Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814 [TBL] [Abstract][Full Text] [Related]
18. Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach. Pereira-Silva M; Diaz-Gomez L; Blanco-Fernandez B; Ferreirós A; Veiga F; Concheiro A; Paiva-Santos AC; Alvarez-Lorenzo C Int J Pharm; 2024 Sep; 662():124529. PubMed ID: 39084580 [TBL] [Abstract][Full Text] [Related]
19. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules. Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328 [TBL] [Abstract][Full Text] [Related]